Leveraging external controls in clinical trials: estimands, estimation, assumptions.

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Bo Liu, Fan Li, Rury R Holman, Laine E Thomas
{"title":"Leveraging external controls in clinical trials: estimands, estimation, assumptions.","authors":"Bo Liu, Fan Li, Rury R Holman, Laine E Thomas","doi":"10.1080/10543406.2026.2685275","DOIUrl":null,"url":null,"abstract":"<p><p>It is increasingly common to augment randomized controlled trial with external controls from observational data, to evaluate the treatment effect of an intervention. Traditional approaches to treatment effect estimation involve ambiguous estimands and unrealistic or strong assumptions, such as mean exchangeability. We introduce a double-indexed notation for potential outcomes to define causal estimands transparently and clarify distinct sources of implicit bias. We show that the concurrent control arm is critical in assessing the plausibility of assumptions and providing unbiased causal estimation. We derive a consistent and locally efficient estimator for a class of weighted average treatment effect estimands that combines concurrent and external data without assuming mean exchangeability. This estimator incorporates an estimate of the systematic difference in outcomes between the concurrent and external units, of which we propose a Frisch-Waugh-Lovell style partial regression method to obtain. We compare the proposed methods with existing methods using extensive simulation and applied to cardiovascular clinical trials.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-16"},"PeriodicalIF":1.3000,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2026.2685275","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

It is increasingly common to augment randomized controlled trial with external controls from observational data, to evaluate the treatment effect of an intervention. Traditional approaches to treatment effect estimation involve ambiguous estimands and unrealistic or strong assumptions, such as mean exchangeability. We introduce a double-indexed notation for potential outcomes to define causal estimands transparently and clarify distinct sources of implicit bias. We show that the concurrent control arm is critical in assessing the plausibility of assumptions and providing unbiased causal estimation. We derive a consistent and locally efficient estimator for a class of weighted average treatment effect estimands that combines concurrent and external data without assuming mean exchangeability. This estimator incorporates an estimate of the systematic difference in outcomes between the concurrent and external units, of which we propose a Frisch-Waugh-Lovell style partial regression method to obtain. We compare the proposed methods with existing methods using extensive simulation and applied to cardiovascular clinical trials.

在临床试验中利用外部控制:估计、估计、假设。
在随机对照试验的基础上加入观察性数据的外部对照,以评估干预措施的治疗效果,这一做法越来越普遍。传统的治疗效果估计方法包括模棱两可的估计和不切实际或强假设,如平均可交换性。我们为潜在结果引入了双索引符号,以透明地定义因果估计,并澄清隐含偏差的不同来源。我们表明,并发控制臂是评估假设的合理性和提供无偏的因果估计的关键。我们推导了一类加权平均处理效果估计的一致和局部有效估计,该估计结合了并发数据和外部数据,而不假设平均可交换性。该估计量包含了对并发单元和外部单元之间结果的系统差异的估计,我们提出了一种Frisch-Waugh-Lovell风格的部分回归方法来获得。我们将提出的方法与现有的方法进行了比较,并应用于心血管临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书